Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 7, 2012, Pages 1629-1639

  Nakagami, Hironori ^a,b   Nishikawa, Tomoyuki ^a   Tamura, Nao ^c   Maeda, Akito ^b   Hibino, Hajime ^d   Mochizuki, Masayoshi ^d   Shimosato, Takashi ^e   Moriya, Toshinori ^e   Morishita, Ryuichi ^a   Tamai, Katsuto ^a   Tomono, Kazunori ^a   Kaneda, Yasufumi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c AnGes MG Inc   (Japan)

^d Peptide Institute Inc   (Japan)

^e Research Department   (Japan)

Author keywords

Angiogenesis; Antimicrobial; Drug development; Translational research

Indexed keywords

AG30 5C PEPTIDE; AG30 PEPTIDE; AG30-5C PEPTIDE; ANGIOGENIC PROTEIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; PEPTIDE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; CELL MOTION; CIRCULAR DICHROISM; DRUG DESIGN; DRUG EFFECT; FEASIBILITY STUDY; GROWTH, DEVELOPMENT AND AGING; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MOUSE; PSEUDOMONAS AERUGINOSA; SYNTHESIS; WOUND HEALING;

ANGIOGENIC PROTEINS; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL LINE; CELL MOVEMENT; CIRCULAR DICHROISM; DRUG DESIGN; FEASIBILITY STUDIES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PSEUDOMONAS AERUGINOSA; WOUND HEALING;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PSEUDOMONAS AERUGINOSA;

EID: 84863088882     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01406.x     Document Type: Article

References (21)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002; 415: 389-95.
2. Hancock RE, Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord. 2002; 2: 79-83.
3. Giangaspero A, Sandri L, Tossi A. Amphipathic alpha helical antimicrobial peptides. Eur J Biochem. 2001; 268: 5589-600.
4. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers. 2002; 66: 236-48.
5. Sorensen O, Bratt T, Johnsen AH, et al. The human antibacterial cathelicidin, hCAP-18, is bound to lipoproteins in plasma. J Biol Chem. 1999; 274: 22445-51.
6. Nishikawa T, Nakagami H, Maeda A, et al. Development of a novel antimicrobial peptide, AG-30, with angiogenic properties. J Cell Mol Med. 2008; 13: 535-46.
7. Rikitake Y, Hirata K, Kawashima S, et al. Involvement of endothelial nitric oxide in sphingosine-1-phosphate-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2002; 22: 108-14.
8. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest. 2003; 111: 1665-72.
9. Boman HG. Antibacterial peptides: basic facts and emerging concepts. J Intern Med. 2003; 254: 197-215.
10. Hunter HN, Jing W, Schibli DJ, et al. The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim Biophys Acta. 2005; 1668: 175-89.
11. Jimenez MA, Evangelio JA, Aranda C, et al. Helicity of alpha(404-451) and beta(394-445) tubulin C-terminal recombinant peptides. Protein Sci. 1999; 8: 788-99.
12. Cho CH, Sung HK, Kim KT, et al. COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model. Proc Natl Acad Sci USA. 2006; 103: 4946-51.
13. Nakagami H, Maeda K, Morishita R, et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol. 2005; 25: 2542-7.
14. Kunigiza Y, Tomita N, Taniyama Y, et al. Acceleration of wound healing by combined gene therapy of hepatocyte growth factor and prostacyclin synthase with Shima jet. Gene Ther. 2006; 13: 1143-52.
15. D'Andrea LD, Iaccarino G, Fattorusso R, et al. Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. Proc Natl Acad Sci USA. 2005; 102: 14215-20.
16. Azuma J, Taniyama Y, Takeya Y, et al. Angiogenic and antifibrotic actions of hepatocyte growth factor improve cardiac dysfunction in porcine ischemic cariomyopathy. Gene Ther. 2006; 13: 1206-13.
17. Munoz V, Serrano L. Elucidating the folding problem of helical peptides using empirical parameters. Nat Struct Biol. 1994; 1: 399-409.
18. Petukhov M, Munoz V, Yumoto N, et al. Position dependence of non-polar amino acid intrinsic helical propensities. J Mol Biol. 1998; 278: 279-89.
19. Venyaminov S, Baikalov IA, Wu CS, et al. Some problems of CD analyses of protein conformation. Anal Biochem. 1991; 198: 250-5.
20. Yano K, Brown LF, Detmar M. Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest. 2001; 107: 409-17.
21. Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother. 2006; 7: 653-63.